Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease.

International journal of molecular sciences - 15 Feb 2023

Dinur Tama, Bauer Peter, Beetz Christian, Cozma Claudia, Becker-Cohen Michal, Istaiti Majdolen, Rolfs Arndt, Skrahina Volha, Zimran Ari, Revel-Vilk Shoshana

Abstract excerpt

Glucosylsphingosine (lyso-Gb1), the deacylated form of glucocerebroside, was shown to be the most specific and sensitive biomarker for diagnosing Gaucher disease (GD). The aim of this study is to assess the contribution of lyso-Gb1 at the time of diagnosis for treatment decisions in naïve patients with GD. Newly diagnosed patients from July 2014 to November 2022 were included in this retrospective cohort study....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to Child, Preschool

Share to Gaucher Disease

Share to Infant

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 36835356
DOI: 10.3390/ijms24043945
PMCID: PMC9966520

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease.PMID 36835356Read ↗

Gaucher Disease Diagnosis Using Lyso-Gb1 on Dry Blood Spot Samples: Time to Change the Paradigm?Semantic proximity Read ↗

Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1Semantic proximity Read ↗

Glucosylsphingosine is a reliable response biomarker in G aucher diseaseSemantic proximity Read ↗

Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson's disease.Semantic proximity Read ↗

Plasma Glucosylsphingosine in GBA1 E365K, N409S, and L483P Heterozygous Mutation Carriers.Semantic proximity Read ↗

Association between plasma glucosylsphingosine levels and dyskinesia burden in GBA1-related Parkinson's disease.Semantic proximity Read ↗

LC-MS/MS analysis of plasma glucosylsphingosine as a biomarker for diagnosis and follow-up monitoring in Gaucher disease in the Spanish population.Semantic proximity Read ↗

Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a Non-Jewish, Caucasian Cohort of Gaucher Disease PatientsSemantic proximity Read ↗

Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease.Semantic proximity Read ↗

An Overview of Gaucher DiseaseSemantic proximity Read ↗

Clinicogenetic Profile, Treatment Modalities, and Mortality Predictors of Gaucher Disease: A 15-Year Retrospective Study.Semantic proximity Read ↗

Recent advances in the diagnosis and management of Gaucher disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.